ARIA

Lab Monitoring Panel

Reference ranges, monitoring schedules, and safety alerts for all 25 peptides

Category:

Peptides

25

AOD-9604

Metabolic

Modified fragment of hGH amino acids 176-191. Developed as a lipolytic agent mimicking GH's fat-metabolizing effects without affecting blood glucose or IGF-1. Phase 2 trials showed modest weight loss. Abandoned by developer but remains available in peptide form.

Monitoring: Baseline, then every 3 months.

Baseline Labs (Before Starting)

Fasting Glucose
Normal: 70-100 mg/dL
IGF-1 (Insulin-like Growth Factor 1)
Normal: 115-340 ng/mL
Lipid Panel
Normal: LDL<100, HDL>40, TG<150 mg/dL
Liver Function (ALT/AST)
Normal: ALT 7-56, AST 10-40 U/L
Comprehensive Metabolic Panel
Normal: See components various

During Treatment

Fasting Glucose
Normal: 70-100 mg/dL
IGF-1 (Insulin-like Growth Factor 1)
Normal: 115-340 ng/mL
Lipid Panel
Normal: LDL<100, HDL>40, TG<150 mg/dL

Critical Alerts

Significant glucose elevation (unlikely but monitor)
IGF-1 >400 ng/mL

Expected Changes

↓ Body fat (visceral > subcutaneous)
Minimal effect on glucose or IGF-1 (advantage over GH)
Possible ↓ triglycerides

Clinical Notes

GH fragment (176-191) — lipolytic without GH systemic effects. Does NOT significantly raise IGF-1 or affect glucose. Safer metabolic profile than full GH. Limited long-term human data.

Clinical Disclaimer: Reference ranges and monitoring recommendations are based on published literature and clinical guidelines. Ranges may vary by laboratory. Always verify against your lab's specific reference ranges. This tool does not replace clinical judgment. Adjust monitoring frequency based on individual patient factors, comorbidities, and treatment response.